Several classes of medications improve cardiovascular and kidney outcomes in patients with type 2 diabetes and CKD, including angiotensin-converting enzyme inhibitors (ACEi) [7], angiotensin receptor blockers (ARBs) [8], sodium-glucose cotransporter-2 inhibitors (SGLT2i) [9], and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone [10, 11]
Rebound was most pronounced post-discontinuation, with semaglutide 2.4 mg showing an MD of approximately -5.15 kg and exenatide approximately -3.06 kg, reflecting substantial regression toward baseline weights within a few months after therapy cessation
START YOUR WEGOVY CONSULTATION This users weight loss wasn't entirely straightforward before starting Wegovy, as they struggled with weight fluctuations
Pro tip : If you go through all the proper steps to try and get a GLP-1 medication covered and still can't get it through your insurance, there are some other options for bringing the cost of medications down
Some practices have staff dedicated to navigating prior authorizations, and knowing this resource exists can save you weeks of frustration
